These findings can support the development of novel synthetic lethality-based therapeutic approaches that exploit USP22 deficiency to improve the outcomes of cancer patients whose tumors exhibit reduced USP22 expression, within a precision medicine framework. This evidence concerns the gene USP22 and cancer.